{"acquisitions":[],"changes":[],"country":"US","description":"Tenvie Therapeutics develops brain-penetrant small-molecule drugs targeting inflammation, metabolic dysfunction, and lysosomal pathways, led by an NLRP3 inhibitor (TNV262) and an allosteric SARM1 inhibitor. It treats neurological, cardiometabolic, and ophthalmic disease. Tenvie inherits a pipeline acquired from Denali Therapeutics.","domain":"tenvietx.com","employees":null,"founded":2023,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco","multiples":[],"name":"Tenvie Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":200000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-08","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"tenvietx-com-2025-01-08-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"tenvietx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"tenvietx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://tenvietx.com"},{"fact":"description","publisher":"tenvietx.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://tenvietx.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":200000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}